Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
about
Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS)The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trialsReduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosisMagnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopyFatigue Management in Multiple SclerosisCervical spinal cord injury: tailoring clinical trial endpoints to reflect meaningful functional improvementsThe role of information system in multiple sclerosis managementPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisSystematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic reviewRevisiting brain atrophy and its relationship to disability in multiple sclerosisMotor fatigue measurement by distance-induced slow down of walking speed in multiple sclerosisThe EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment.Rhythmic cued motor imagery and walking in people with multiple sclerosis: a randomised controlled feasibility study.Possible clinical outcome measures for clinical trials in patients with multiple sclerosisThird ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Assessment set for evaluation of clinical outcomes in multiple sclerosis: psychometric properties.Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testingLongitudinal scalar-on-functions regression with application to tractography data.Reliability of regression-based normative data for the oral symbol digit modalities test: an evaluation of demographic influences, construct validity, and impairment classification rates in multiple sclerosis samples.Web-based physiotherapy for people moderately affected with Multiple Sclerosis; quantitative and qualitative data from a randomized, controlled pilot study.Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis.Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study.The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.The role of MRI in the evaluation of secondary progressive multiple sclerosis.Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.Timed Gait test: normative data for the assessment of the AIDS dementia complex.Outcome Measures in Clinical Trials for Multiple Sclerosis.Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis.Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis.Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
P2860
Q21245611-40F97F8C-7D8E-4DAE-8E6C-C265570307F1Q22241715-C4B71FA2-C2C0-448B-811E-2D5B057B73D7Q24647406-F0D55093-E85D-4F74-98D3-A3D5D39DA2D6Q24800569-2CBF40B7-B081-4075-99DA-850688088CA4Q26752946-72BBC801-7A65-46B2-A48E-95A9C8CB7ACFQ26823368-371C3458-D97D-41F8-955B-80A01CE88877Q27000124-FAA61B06-B72C-430A-A24C-E08B582E536CQ27000269-BC1DDB52-B92A-4C73-808C-C94989BC4822Q27004079-4E1AB610-3ED4-4F05-B535-AD292CF49B2AQ27007478-BCE0A491-1C70-41F0-B431-489F6FE4CC15Q28729953-8B9B9A13-67E6-4929-A23C-51A0281513D4Q28730575-ED546F56-68FE-498F-B3CA-FD4C0C572CA3Q30277106-226C4BEB-00F1-42E4-93CD-459F64932C9FQ30392522-84F14122-3BD2-4FC3-A0EC-AC616FD7861EQ30396391-6E1E98A0-7F55-444E-AA84-3C947881A331Q30433837-C010F670-A32F-45AA-A1B0-0E0B29E18577Q30449269-1AF33ABB-F702-4A18-91B3-5C1DEB5DF56FQ30458930-66150116-5724-4303-A6A9-4B0E97A3CC60Q30460601-18260633-7520-4DB2-9A08-8621904DAE32Q30474902-27291F98-0875-454F-9E79-928AFF1F392FQ30496995-277E8751-5C04-4472-90C6-53627A9669A4Q30584750-E2954FC0-342B-400C-9CAD-3AF47C6DBD20Q30736446-F750A650-0465-41BF-A9C8-1124D26C53F6Q30791242-74CBEB41-EAD9-432B-A212-26DC46462242Q30814336-E4981707-9E97-4F8B-AEB9-1DC0EC54BF4BQ30866592-B0DF2CDB-F1F7-4A64-AE69-3266E812B319Q30928115-852FAF42-9F2E-4DE7-A055-032F559F1976Q30932853-41B2B16E-61C2-4C6D-961C-AFFD64E23F42Q30953733-B4C53B08-3078-4028-8DD6-38E68BEDC22FQ31033345-21868600-A2B9-42F8-A434-124287C794FAQ31037055-0360C71A-BB4D-425C-81CD-5F1FC18E1987Q31048720-4174CFB6-F7F9-4372-82F4-BA26811F768CQ31160866-B9B61067-ABE5-4A2D-9632-51AD4DD1D259Q33194284-2A1B66DF-AC37-4838-92C2-A148F2ACA32CQ33455446-2070BE7F-5022-4388-A548-F94C41B95A47Q33520391-B2569DC5-688E-41F6-A58D-0F071D1E3A88Q33556095-27C937E7-857B-4E65-B24F-9F75D21A46ABQ33589958-15436FEF-5C7C-43C2-9E69-C4E62B96FA59Q33605310-04906D2D-529B-46F7-8883-217E96579703Q33605353-EBDBD8C7-A5BA-430E-AE84-FD6563BFC954
P2860
Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Development of a multiple scle ...... linical trial outcome measure.
@en
type
label
Development of a multiple scle ...... linical trial outcome measure.
@en
prefLabel
Development of a multiple scle ...... linical trial outcome measure.
@en
P2093
P356
P1433
P1476
Development of a multiple scle ...... linical trial outcome measure.
@en
P2093
Confavreux C
Cookfair DL
Ellison GW
Fischer JS
P304
P356
10.1093/BRAIN/122.5.871
P407
P478
122 ( Pt 5)
P577
1999-05-01T00:00:00Z